nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—CA9—cervical cancer	0.495	1	CbGaD
Nilotinib—ABCG2—Topotecan—cervical cancer	0.109	0.634	CbGbCtD
Nilotinib—ABCB1—Topotecan—cervical cancer	0.0394	0.229	CbGbCtD
Nilotinib—CYP3A4—Topotecan—cervical cancer	0.0236	0.137	CbGbCtD
Nilotinib—Pleuritic pain—Topotecan—cervical cancer	0.00548	0.113	CcSEcCtD
Nilotinib—Ponatinib—FGFR3—cervical cancer	0.00507	0.79	CrCbGaD
Nilotinib—EPHB2—Irinotecan—Topotecan—cervical cancer	0.00482	1	CbGdCrCtD
Nilotinib—MAPK8—exocrine gland—cervical cancer	0.0027	0.0213	CbGeAlD
Nilotinib—Myelosuppression—Topotecan—cervical cancer	0.00235	0.0482	CcSEcCtD
Nilotinib—CA6—exocrine gland—cervical cancer	0.00194	0.0153	CbGeAlD
Nilotinib—Febrile neutropenia—Topotecan—cervical cancer	0.00183	0.0375	CcSEcCtD
Nilotinib—Interstitial lung disease—Topotecan—cervical cancer	0.00155	0.0319	CcSEcCtD
Nilotinib—Pleural effusion—Topotecan—cervical cancer	0.00144	0.0295	CcSEcCtD
Nilotinib—FRK—renal system—cervical cancer	0.00143	0.0112	CbGeAlD
Nilotinib—Imatinib—CA9—cervical cancer	0.00134	0.21	CrCbGaD
Nilotinib—CDC42BPB—uterine cervix—cervical cancer	0.00129	0.0101	CbGeAlD
Nilotinib—CDC42BPB—decidua—cervical cancer	0.00123	0.00966	CbGeAlD
Nilotinib—Hyperbilirubinaemia—Topotecan—cervical cancer	0.00121	0.0248	CcSEcCtD
Nilotinib—CDC42BPB—renal system—cervical cancer	0.0012	0.00948	CbGeAlD
Nilotinib—MAPK8—epithelium—cervical cancer	0.00117	0.00924	CbGeAlD
Nilotinib—MAPK8—uterine cervix—cervical cancer	0.00116	0.00917	CbGeAlD
Nilotinib—Blood bilirubin increased—Topotecan—cervical cancer	0.00116	0.0239	CcSEcCtD
Nilotinib—Bone pain—Topotecan—cervical cancer	0.00115	0.0236	CcSEcCtD
Nilotinib—FRK—female reproductive system—cervical cancer	0.00114	0.009	CbGeAlD
Nilotinib—KIT—exocrine gland—cervical cancer	0.00113	0.00887	CbGeAlD
Nilotinib—MAPK8—renal system—cervical cancer	0.00109	0.00857	CbGeAlD
Nilotinib—CDC42BPB—uterus—cervical cancer	0.00107	0.00845	CbGeAlD
Nilotinib—TIE1—epithelium—cervical cancer	0.00102	0.00802	CbGeAlD
Nilotinib—TIE1—uterine cervix—cervical cancer	0.00101	0.00795	CbGeAlD
Nilotinib—MAP4K1—decidua—cervical cancer	0.00101	0.00794	CbGeAlD
Nilotinib—Neoplasm—Topotecan—cervical cancer	0.000995	0.0204	CcSEcCtD
Nilotinib—MAPK11—female reproductive system—cervical cancer	0.000972	0.00766	CbGeAlD
Nilotinib—MAPK8—uterus—cervical cancer	0.00097	0.00764	CbGeAlD
Nilotinib—CDC42BPB—female reproductive system—cervical cancer	0.000964	0.00759	CbGeAlD
Nilotinib—TIE1—decidua—cervical cancer	0.000961	0.00757	CbGeAlD
Nilotinib—EPHB3—uterine cervix—cervical cancer	0.00096	0.00756	CbGeAlD
Nilotinib—Sepsis—Topotecan—cervical cancer	0.000955	0.0196	CcSEcCtD
Nilotinib—Ear pain—Topotecan—cervical cancer	0.000936	0.0192	CcSEcCtD
Nilotinib—MAP4K1—mammalian vulva—cervical cancer	0.000925	0.00729	CbGeAlD
Nilotinib—MAPK11—female gonad—cervical cancer	0.000884	0.00697	CbGeAlD
Nilotinib—HCK—uterine cervix—cervical cancer	0.000882	0.00695	CbGeAlD
Nilotinib—CDC42BPB—female gonad—cervical cancer	0.000877	0.00691	CbGeAlD
Nilotinib—BRAF—endometrium—cervical cancer	0.000875	0.00689	CbGeAlD
Nilotinib—CDC42BPB—vagina—cervical cancer	0.000872	0.00687	CbGeAlD
Nilotinib—MAPK8—female reproductive system—cervical cancer	0.000872	0.00687	CbGeAlD
Nilotinib—EPHA6—female reproductive system—cervical cancer	0.000872	0.00687	CbGeAlD
Nilotinib—EPHB3—endometrium—cervical cancer	0.000868	0.00684	CbGeAlD
Nilotinib—TIE1—uterus—cervical cancer	0.000841	0.00662	CbGeAlD
Nilotinib—HCK—decidua—cervical cancer	0.00084	0.00662	CbGeAlD
Nilotinib—EPHB3—mammalian vulva—cervical cancer	0.00084	0.00661	CbGeAlD
Nilotinib—Dermatitis bullous—Topotecan—cervical cancer	0.000836	0.0172	CcSEcCtD
Nilotinib—Lethargy—Topotecan—cervical cancer	0.000815	0.0167	CcSEcCtD
Nilotinib—CA7—renal system—cervical cancer	0.000807	0.00636	CbGeAlD
Nilotinib—BRAF—uterus—cervical cancer	0.000806	0.00635	CbGeAlD
Nilotinib—EPHB3—uterus—cervical cancer	0.0008	0.0063	CbGeAlD
Nilotinib—HCK—endometrium—cervical cancer	0.000798	0.00628	CbGeAlD
Nilotinib—MAPK8—female gonad—cervical cancer	0.000793	0.00625	CbGeAlD
Nilotinib—CA3—uterine cervix—cervical cancer	0.000792	0.00624	CbGeAlD
Nilotinib—MAPK8—vagina—cervical cancer	0.000789	0.00621	CbGeAlD
Nilotinib—HCK—mammalian vulva—cervical cancer	0.000772	0.00608	CbGeAlD
Nilotinib—TIE1—female reproductive system—cervical cancer	0.000756	0.00595	CbGeAlD
Nilotinib—MAPK14—epithelium—cervical cancer	0.000745	0.00587	CbGeAlD
Nilotinib—MAPK14—uterine cervix—cervical cancer	0.000739	0.00582	CbGeAlD
Nilotinib—LCK—uterine cervix—cervical cancer	0.000736	0.0058	CbGeAlD
Nilotinib—HCK—uterus—cervical cancer	0.000735	0.00579	CbGeAlD
Nilotinib—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.000719	0.0148	CcSEcCtD
Nilotinib—EPHB3—female reproductive system—cervical cancer	0.000719	0.00566	CbGeAlD
Nilotinib—MAP4K1—vagina—cervical cancer	0.000717	0.00564	CbGeAlD
Nilotinib—EPHB4—epithelium—cervical cancer	0.000707	0.00557	CbGeAlD
Nilotinib—Alanine aminotransferase increased—Topotecan—cervical cancer	0.000704	0.0145	CcSEcCtD
Nilotinib—MAPK14—decidua—cervical cancer	0.000704	0.00555	CbGeAlD
Nilotinib—LCK—decidua—cervical cancer	0.000701	0.00552	CbGeAlD
Nilotinib—FGR—decidua—cervical cancer	0.000701	0.00552	CbGeAlD
Nilotinib—EPHA4—mammalian vulva—cervical cancer	0.000701	0.00552	CbGeAlD
Nilotinib—EPHB4—uterine cervix—cervical cancer	0.000701	0.00552	CbGeAlD
Nilotinib—EPHA2—epithelium—cervical cancer	0.000693	0.00546	CbGeAlD
Nilotinib—MAPK14—renal system—cervical cancer	0.000691	0.00545	CbGeAlD
Nilotinib—TIE1—female gonad—cervical cancer	0.000688	0.00542	CbGeAlD
Nilotinib—EPHA2—uterine cervix—cervical cancer	0.000687	0.00541	CbGeAlD
Nilotinib—TEK—epithelium—cervical cancer	0.000676	0.00533	CbGeAlD
Nilotinib—EPHA4—uterus—cervical cancer	0.000668	0.00526	CbGeAlD
Nilotinib—EPHB4—decidua—cervical cancer	0.000667	0.00526	CbGeAlD
Nilotinib—CA2—exocrine gland—cervical cancer	0.000667	0.00526	CbGeAlD
Nilotinib—FGR—endometrium—cervical cancer	0.000666	0.00524	CbGeAlD
Nilotinib—CA3—uterus—cervical cancer	0.00066	0.0052	CbGeAlD
Nilotinib—BRAF—female gonad—cervical cancer	0.000659	0.00519	CbGeAlD
Nilotinib—Pancytopenia—Topotecan—cervical cancer	0.000656	0.0135	CcSEcCtD
Nilotinib—BRAF—vagina—cervical cancer	0.000655	0.00516	CbGeAlD
Nilotinib—EPHB4—renal system—cervical cancer	0.000655	0.00516	CbGeAlD
Nilotinib—EPHA2—decidua—cervical cancer	0.000655	0.00516	CbGeAlD
Nilotinib—EPHB3—female gonad—cervical cancer	0.000654	0.00515	CbGeAlD
Nilotinib—EPHB3—vagina—cervical cancer	0.00065	0.00512	CbGeAlD
Nilotinib—Neutropenia—Topotecan—cervical cancer	0.000645	0.0133	CcSEcCtD
Nilotinib—BLK—lymph node—cervical cancer	0.000645	0.00508	CbGeAlD
Nilotinib—LCK—mammalian vulva—cervical cancer	0.000644	0.00507	CbGeAlD
Nilotinib—FGR—mammalian vulva—cervical cancer	0.000644	0.00507	CbGeAlD
Nilotinib—EPHB6—uterine cervix—cervical cancer	0.000641	0.00505	CbGeAlD
Nilotinib—TEK—decidua—cervical cancer	0.000639	0.00503	CbGeAlD
Nilotinib—EPHB4—endometrium—cervical cancer	0.000634	0.00499	CbGeAlD
Nilotinib—Weight increased—Topotecan—cervical cancer	0.000628	0.0129	CcSEcCtD
Nilotinib—TEK—renal system—cervical cancer	0.000627	0.00494	CbGeAlD
Nilotinib—EPHA2—endometrium—cervical cancer	0.000622	0.0049	CbGeAlD
Nilotinib—Pneumonia—Topotecan—cervical cancer	0.000619	0.0127	CcSEcCtD
Nilotinib—MAPK14—uterus—cervical cancer	0.000616	0.00485	CbGeAlD
Nilotinib—Infestation—Topotecan—cervical cancer	0.000615	0.0126	CcSEcCtD
Nilotinib—Infestation NOS—Topotecan—cervical cancer	0.000615	0.0126	CcSEcCtD
Nilotinib—LCK—uterus—cervical cancer	0.000613	0.00483	CbGeAlD
Nilotinib—EPHB4—mammalian vulva—cervical cancer	0.000613	0.00483	CbGeAlD
Nilotinib—EPHB6—decidua—cervical cancer	0.00061	0.00481	CbGeAlD
Nilotinib—TEK—endometrium—cervical cancer	0.000606	0.00478	CbGeAlD
Nilotinib—Neuropathy peripheral—Topotecan—cervical cancer	0.000603	0.0124	CcSEcCtD
Nilotinib—EPHA2—mammalian vulva—cervical cancer	0.000601	0.00474	CbGeAlD
Nilotinib—HCK—female gonad—cervical cancer	0.000601	0.00474	CbGeAlD
Nilotinib—EPHA4—female reproductive system—cervical cancer	0.000601	0.00473	CbGeAlD
Nilotinib—Stomatitis—Topotecan—cervical cancer	0.0006	0.0123	CcSEcCtD
Nilotinib—HCK—vagina—cervical cancer	0.000598	0.00471	CbGeAlD
Nilotinib—ABL2—female gonad—cervical cancer	0.000597	0.00471	CbGeAlD
Nilotinib—ABL2—vagina—cervical cancer	0.000594	0.00468	CbGeAlD
Nilotinib—EPHB4—uterus—cervical cancer	0.000584	0.0046	CbGeAlD
Nilotinib—Hepatobiliary disease—Topotecan—cervical cancer	0.000582	0.012	CcSEcCtD
Nilotinib—Epistaxis—Topotecan—cervical cancer	0.000581	0.0119	CcSEcCtD
Nilotinib—EPHB6—endometrium—cervical cancer	0.00058	0.00456	CbGeAlD
Nilotinib—PDGFRA—decidua—cervical cancer	0.000579	0.00456	CbGeAlD
Nilotinib—MAPK11—lymph node—cervical cancer	0.000569	0.00448	CbGeAlD
Nilotinib—PDGFRA—renal system—cervical cancer	0.000568	0.00448	CbGeAlD
Nilotinib—CA9—female reproductive system—cervical cancer	0.000568	0.00447	CbGeAlD
Nilotinib—CDC42BPB—lymph node—cervical cancer	0.000564	0.00444	CbGeAlD
Nilotinib—EPHB6—mammalian vulva—cervical cancer	0.000561	0.00442	CbGeAlD
Nilotinib—TEK—uterus—cervical cancer	0.000559	0.0044	CbGeAlD
Nilotinib—Haemoglobin—Topotecan—cervical cancer	0.000555	0.0114	CcSEcCtD
Nilotinib—Rhinitis—Topotecan—cervical cancer	0.000554	0.0114	CcSEcCtD
Nilotinib—MAPK14—female reproductive system—cervical cancer	0.000554	0.00436	CbGeAlD
Nilotinib—Haemorrhage—Topotecan—cervical cancer	0.000553	0.0113	CcSEcCtD
Nilotinib—FGR—female reproductive system—cervical cancer	0.000551	0.00434	CbGeAlD
Nilotinib—Hypoaesthesia—Topotecan—cervical cancer	0.00055	0.0113	CcSEcCtD
Nilotinib—Pharyngitis—Topotecan—cervical cancer	0.000548	0.0113	CcSEcCtD
Nilotinib—MAP2K5—uterine cervix—cervical cancer	0.000548	0.00432	CbGeAlD
Nilotinib—EPHA4—female gonad—cervical cancer	0.000546	0.0043	CbGeAlD
Nilotinib—EPHA4—vagina—cervical cancer	0.000543	0.00428	CbGeAlD
Nilotinib—UGT1A1—renal system—cervical cancer	0.000542	0.00427	CbGeAlD
Nilotinib—CA3—vagina—cervical cancer	0.000536	0.00423	CbGeAlD
Nilotinib—CSF1R—uterine cervix—cervical cancer	0.000535	0.00421	CbGeAlD
Nilotinib—EPHA3—lymph node—cervical cancer	0.000535	0.00421	CbGeAlD
Nilotinib—EPHB4—female reproductive system—cervical cancer	0.000525	0.00413	CbGeAlD
Nilotinib—CA12—renal system—cervical cancer	0.000524	0.00413	CbGeAlD
Nilotinib—MAP2K5—decidua—cervical cancer	0.000522	0.00411	CbGeAlD
Nilotinib—EPHA2—female reproductive system—cervical cancer	0.000515	0.00406	CbGeAlD
Nilotinib—MAPK8—lymph node—cervical cancer	0.00051	0.00402	CbGeAlD
Nilotinib—CSF1R—decidua—cervical cancer	0.00051	0.00401	CbGeAlD
Nilotinib—PDGFRA—uterus—cervical cancer	0.000506	0.00399	CbGeAlD
Nilotinib—MAPK14—female gonad—cervical cancer	0.000504	0.00397	CbGeAlD
Nilotinib—TEK—female reproductive system—cervical cancer	0.000502	0.00396	CbGeAlD
Nilotinib—LCK—female gonad—cervical cancer	0.000502	0.00395	CbGeAlD
Nilotinib—FGR—female gonad—cervical cancer	0.000502	0.00395	CbGeAlD
Nilotinib—Angiopathy—Topotecan—cervical cancer	0.000501	0.0103	CcSEcCtD
Nilotinib—MAPK14—vagina—cervical cancer	0.000501	0.00394	CbGeAlD
Nilotinib—Immune system disorder—Topotecan—cervical cancer	0.000499	0.0102	CcSEcCtD
Nilotinib—FGR—vagina—cervical cancer	0.000499	0.00393	CbGeAlD
Nilotinib—LCK—vagina—cervical cancer	0.000499	0.00393	CbGeAlD
Nilotinib—Mediastinal disorder—Topotecan—cervical cancer	0.000498	0.0102	CcSEcCtD
Nilotinib—Chills—Topotecan—cervical cancer	0.000496	0.0102	CcSEcCtD
Nilotinib—MAP2K5—endometrium—cervical cancer	0.000496	0.0039	CbGeAlD
Nilotinib—KIT—epithelium—cervical cancer	0.00049	0.00386	CbGeAlD
Nilotinib—Alopecia—Topotecan—cervical cancer	0.000488	0.01	CcSEcCtD
Nilotinib—KIT—uterine cervix—cervical cancer	0.000486	0.00383	CbGeAlD
Nilotinib—CSF1R—endometrium—cervical cancer	0.000484	0.00381	CbGeAlD
Nilotinib—Malnutrition—Topotecan—cervical cancer	0.000481	0.00987	CcSEcCtD
Nilotinib—MAP2K5—mammalian vulva—cervical cancer	0.000479	0.00378	CbGeAlD
Nilotinib—PDGFRB—epithelium—cervical cancer	0.000478	0.00377	CbGeAlD
Nilotinib—EPHB4—female gonad—cervical cancer	0.000478	0.00376	CbGeAlD
Nilotinib—EPHB4—vagina—cervical cancer	0.000475	0.00374	CbGeAlD
Nilotinib—PDGFRB—uterine cervix—cervical cancer	0.000474	0.00374	CbGeAlD
Nilotinib—EPHA2—female gonad—cervical cancer	0.000469	0.00369	CbGeAlD
Nilotinib—CSF1R—mammalian vulva—cervical cancer	0.000468	0.00369	CbGeAlD
Nilotinib—EPHA2—vagina—cervical cancer	0.000466	0.00367	CbGeAlD
Nilotinib—Back pain—Topotecan—cervical cancer	0.000465	0.00955	CcSEcCtD
Nilotinib—MAP4K1—lymph node—cervical cancer	0.000464	0.00365	CbGeAlD
Nilotinib—KIT—decidua—cervical cancer	0.000463	0.00364	CbGeAlD
Nilotinib—Muscle spasms—Topotecan—cervical cancer	0.000462	0.00949	CcSEcCtD
Nilotinib—TEK—female gonad—cervical cancer	0.000457	0.0036	CbGeAlD
Nilotinib—PDGFRA—female reproductive system—cervical cancer	0.000455	0.00358	CbGeAlD
Nilotinib—KIT—renal system—cervical cancer	0.000454	0.00358	CbGeAlD
Nilotinib—PDGFRB—decidua—cervical cancer	0.000452	0.00356	CbGeAlD
Nilotinib—Ill-defined disorder—Topotecan—cervical cancer	0.000446	0.00916	CcSEcCtD
Nilotinib—CSF1R—uterus—cervical cancer	0.000446	0.00351	CbGeAlD
Nilotinib—Anaemia—Topotecan—cervical cancer	0.000445	0.00913	CcSEcCtD
Nilotinib—PDGFRB—renal system—cervical cancer	0.000444	0.0035	CbGeAlD
Nilotinib—TIE1—lymph node—cervical cancer	0.000442	0.00348	CbGeAlD
Nilotinib—KIT—endometrium—cervical cancer	0.000439	0.00346	CbGeAlD
Nilotinib—EPHB6—female gonad—cervical cancer	0.000437	0.00344	CbGeAlD
Nilotinib—EPHB6—vagina—cervical cancer	0.000434	0.00342	CbGeAlD
Nilotinib—Malaise—Topotecan—cervical cancer	0.000434	0.0089	CcSEcCtD
Nilotinib—Leukopenia—Topotecan—cervical cancer	0.000431	0.00884	CcSEcCtD
Nilotinib—PDGFRB—endometrium—cervical cancer	0.000429	0.00338	CbGeAlD
Nilotinib—KIT—mammalian vulva—cervical cancer	0.000425	0.00335	CbGeAlD
Nilotinib—BRAF—lymph node—cervical cancer	0.000424	0.00334	CbGeAlD
Nilotinib—ABL1—uterine cervix—cervical cancer	0.000423	0.00333	CbGeAlD
Nilotinib—EPHB3—lymph node—cervical cancer	0.000421	0.00331	CbGeAlD
Nilotinib—CA12—female reproductive system—cervical cancer	0.00042	0.00331	CbGeAlD
Nilotinib—Cough—Topotecan—cervical cancer	0.00042	0.00862	CcSEcCtD
Nilotinib—CA1—renal system—cervical cancer	0.000416	0.00327	CbGeAlD
Nilotinib—PDGFRB—mammalian vulva—cervical cancer	0.000415	0.00327	CbGeAlD
Nilotinib—PDGFRA—female gonad—cervical cancer	0.000414	0.00326	CbGeAlD
Nilotinib—PDGFRA—vagina—cervical cancer	0.000412	0.00324	CbGeAlD
Nilotinib—MAP2K5—female reproductive system—cervical cancer	0.000411	0.00323	CbGeAlD
Nilotinib—Arthralgia—Topotecan—cervical cancer	0.000409	0.00841	CcSEcCtD
Nilotinib—Myalgia—Topotecan—cervical cancer	0.000409	0.00841	CcSEcCtD
Nilotinib—Chest pain—Topotecan—cervical cancer	0.000409	0.00841	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.000407	0.00835	CcSEcCtD
Nilotinib—KIT—uterus—cervical cancer	0.000405	0.00319	CbGeAlD
Nilotinib—Discomfort—Topotecan—cervical cancer	0.000405	0.00831	CcSEcCtD
Nilotinib—ABL1—decidua—cervical cancer	0.000403	0.00317	CbGeAlD
Nilotinib—CSF1R—female reproductive system—cervical cancer	0.000401	0.00316	CbGeAlD
Nilotinib—ABL1—renal system—cervical cancer	0.000395	0.00312	CbGeAlD
Nilotinib—PDGFRB—uterus—cervical cancer	0.000395	0.00311	CbGeAlD
Nilotinib—Infection—Topotecan—cervical cancer	0.00039	0.00801	CcSEcCtD
Nilotinib—HCK—lymph node—cervical cancer	0.000387	0.00304	CbGeAlD
Nilotinib—Nervous system disorder—Topotecan—cervical cancer	0.000385	0.0079	CcSEcCtD
Nilotinib—Thrombocytopenia—Topotecan—cervical cancer	0.000384	0.00789	CcSEcCtD
Nilotinib—ABL2—lymph node—cervical cancer	0.000384	0.00303	CbGeAlD
Nilotinib—ABL1—endometrium—cervical cancer	0.000382	0.00301	CbGeAlD
Nilotinib—Skin disorder—Topotecan—cervical cancer	0.000381	0.00783	CcSEcCtD
Nilotinib—Hyperhidrosis—Topotecan—cervical cancer	0.000379	0.00779	CcSEcCtD
Nilotinib—Anorexia—Topotecan—cervical cancer	0.000374	0.00768	CcSEcCtD
Nilotinib—MAP2K5—female gonad—cervical cancer	0.000374	0.00294	CbGeAlD
Nilotinib—MAP2K5—vagina—cervical cancer	0.000371	0.00292	CbGeAlD
Nilotinib—ABL1—mammalian vulva—cervical cancer	0.00037	0.00291	CbGeAlD
Nilotinib—CSF1R—female gonad—cervical cancer	0.000365	0.00287	CbGeAlD
Nilotinib—KIT—female reproductive system—cervical cancer	0.000364	0.00287	CbGeAlD
Nilotinib—CSF1R—vagina—cervical cancer	0.000362	0.00285	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Topotecan—cervical cancer	0.000358	0.00734	CcSEcCtD
Nilotinib—PDGFRB—female reproductive system—cervical cancer	0.000355	0.0028	CbGeAlD
Nilotinib—Paraesthesia—Topotecan—cervical cancer	0.000352	0.00724	CcSEcCtD
Nilotinib—ABL1—uterus—cervical cancer	0.000352	0.00278	CbGeAlD
Nilotinib—EPHA4—lymph node—cervical cancer	0.000351	0.00277	CbGeAlD
Nilotinib—Dyspnoea—Topotecan—cervical cancer	0.00035	0.00718	CcSEcCtD
Nilotinib—CA3—lymph node—cervical cancer	0.000347	0.00273	CbGeAlD
Nilotinib—Dyspepsia—Topotecan—cervical cancer	0.000346	0.00709	CcSEcCtD
Nilotinib—Decreased appetite—Topotecan—cervical cancer	0.000341	0.00701	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Topotecan—cervical cancer	0.000339	0.00696	CcSEcCtD
Nilotinib—Fatigue—Topotecan—cervical cancer	0.000338	0.00695	CcSEcCtD
Nilotinib—Constipation—Topotecan—cervical cancer	0.000336	0.00689	CcSEcCtD
Nilotinib—Pain—Topotecan—cervical cancer	0.000336	0.00689	CcSEcCtD
Nilotinib—CA1—female reproductive system—cervical cancer	0.000333	0.00262	CbGeAlD
Nilotinib—KIT—female gonad—cervical cancer	0.000331	0.00261	CbGeAlD
Nilotinib—KIT—vagina—cervical cancer	0.000329	0.00259	CbGeAlD
Nilotinib—CA4—renal system—cervical cancer	0.000325	0.00256	CbGeAlD
Nilotinib—MAPK14—lymph node—cervical cancer	0.000324	0.00255	CbGeAlD
Nilotinib—Feeling abnormal—Topotecan—cervical cancer	0.000323	0.00664	CcSEcCtD
Nilotinib—PDGFRB—female gonad—cervical cancer	0.000323	0.00255	CbGeAlD
Nilotinib—FGR—lymph node—cervical cancer	0.000323	0.00254	CbGeAlD
Nilotinib—LCK—lymph node—cervical cancer	0.000323	0.00254	CbGeAlD
Nilotinib—PDGFRB—vagina—cervical cancer	0.000321	0.00253	CbGeAlD
Nilotinib—Gastrointestinal pain—Topotecan—cervical cancer	0.000321	0.00659	CcSEcCtD
Nilotinib—ABL1—female reproductive system—cervical cancer	0.000317	0.00249	CbGeAlD
Nilotinib—Urticaria—Topotecan—cervical cancer	0.000312	0.0064	CcSEcCtD
Nilotinib—Body temperature increased—Topotecan—cervical cancer	0.00031	0.00637	CcSEcCtD
Nilotinib—Abdominal pain—Topotecan—cervical cancer	0.00031	0.00637	CcSEcCtD
Nilotinib—EPHB4—lymph node—cervical cancer	0.000307	0.00242	CbGeAlD
Nilotinib—EPHA2—lymph node—cervical cancer	0.000301	0.00237	CbGeAlD
Nilotinib—TEK—lymph node—cervical cancer	0.000294	0.00231	CbGeAlD
Nilotinib—CA2—epithelium—cervical cancer	0.00029	0.00229	CbGeAlD
Nilotinib—Hypersensitivity—Topotecan—cervical cancer	0.000289	0.00594	CcSEcCtD
Nilotinib—ABL1—female gonad—cervical cancer	0.000288	0.00227	CbGeAlD
Nilotinib—ABL1—vagina—cervical cancer	0.000286	0.00226	CbGeAlD
Nilotinib—Asthenia—Topotecan—cervical cancer	0.000282	0.00578	CcSEcCtD
Nilotinib—EPHB6—lymph node—cervical cancer	0.000281	0.00221	CbGeAlD
Nilotinib—Pruritus—Topotecan—cervical cancer	0.000278	0.0057	CcSEcCtD
Nilotinib—CA2—decidua—cervical cancer	0.000274	0.00216	CbGeAlD
Nilotinib—CA2—renal system—cervical cancer	0.000269	0.00212	CbGeAlD
Nilotinib—Diarrhoea—Topotecan—cervical cancer	0.000269	0.00551	CcSEcCtD
Nilotinib—ABCG2—uterine cervix—cervical cancer	0.000267	0.0021	CbGeAlD
Nilotinib—PDGFRA—lymph node—cervical cancer	0.000266	0.0021	CbGeAlD
Nilotinib—CA4—female reproductive system—cervical cancer	0.00026	0.00205	CbGeAlD
Nilotinib—Dizziness—Topotecan—cervical cancer	0.00026	0.00533	CcSEcCtD
Nilotinib—CYP2C8—renal system—cervical cancer	0.000256	0.00202	CbGeAlD
Nilotinib—ABCG2—decidua—cervical cancer	0.000254	0.002	CbGeAlD
Nilotinib—CA2—mammalian vulva—cervical cancer	0.000252	0.00198	CbGeAlD
Nilotinib—Vomiting—Topotecan—cervical cancer	0.00025	0.00512	CcSEcCtD
Nilotinib—CYP2C8—endometrium—cervical cancer	0.000248	0.00195	CbGeAlD
Nilotinib—Rash—Topotecan—cervical cancer	0.000248	0.00508	CcSEcCtD
Nilotinib—Dermatitis—Topotecan—cervical cancer	0.000247	0.00508	CcSEcCtD
Nilotinib—Headache—Topotecan—cervical cancer	0.000246	0.00505	CcSEcCtD
Nilotinib—ABCG2—endometrium—cervical cancer	0.000241	0.0019	CbGeAlD
Nilotinib—MAP2K5—lymph node—cervical cancer	0.00024	0.00189	CbGeAlD
Nilotinib—CA4—female gonad—cervical cancer	0.000237	0.00186	CbGeAlD
Nilotinib—CSF1R—lymph node—cervical cancer	0.000234	0.00185	CbGeAlD
Nilotinib—ABCG2—mammalian vulva—cervical cancer	0.000233	0.00184	CbGeAlD
Nilotinib—Nausea—Topotecan—cervical cancer	0.000233	0.00479	CcSEcCtD
Nilotinib—CYP2B6—renal system—cervical cancer	0.00023	0.00181	CbGeAlD
Nilotinib—ABCG2—uterus—cervical cancer	0.000222	0.00175	CbGeAlD
Nilotinib—CA2—female reproductive system—cervical cancer	0.000216	0.0017	CbGeAlD
Nilotinib—KIT—lymph node—cervical cancer	0.000213	0.00168	CbGeAlD
Nilotinib—PDGFRB—lymph node—cervical cancer	0.000208	0.00164	CbGeAlD
Nilotinib—CYP2C8—female reproductive system—cervical cancer	0.000205	0.00162	CbGeAlD
Nilotinib—CA2—female gonad—cervical cancer	0.000196	0.00155	CbGeAlD
Nilotinib—CA2—vagina—cervical cancer	0.000195	0.00154	CbGeAlD
Nilotinib—CA1—lymph node—cervical cancer	0.000195	0.00153	CbGeAlD
Nilotinib—CYP2C8—vagina—cervical cancer	0.000186	0.00146	CbGeAlD
Nilotinib—ABL1—lymph node—cervical cancer	0.000185	0.00146	CbGeAlD
Nilotinib—CYP2B6—female reproductive system—cervical cancer	0.000184	0.00145	CbGeAlD
Nilotinib—CYP2C9—female reproductive system—cervical cancer	0.000182	0.00144	CbGeAlD
Nilotinib—ABCG2—female gonad—cervical cancer	0.000182	0.00143	CbGeAlD
Nilotinib—ABCG2—vagina—cervical cancer	0.000181	0.00142	CbGeAlD
Nilotinib—CYP3A4—renal system—cervical cancer	0.000174	0.00137	CbGeAlD
Nilotinib—CYP2D6—renal system—cervical cancer	0.000171	0.00135	CbGeAlD
Nilotinib—CYP2B6—vagina—cervical cancer	0.000167	0.00131	CbGeAlD
Nilotinib—CA4—lymph node—cervical cancer	0.000152	0.0012	CbGeAlD
Nilotinib—CYP3A4—female reproductive system—cervical cancer	0.000139	0.0011	CbGeAlD
Nilotinib—CYP2D6—female reproductive system—cervical cancer	0.000137	0.00108	CbGeAlD
Nilotinib—ABCB1—epithelium—cervical cancer	0.000133	0.00104	CbGeAlD
Nilotinib—ABCB1—uterine cervix—cervical cancer	0.000131	0.00104	CbGeAlD
Nilotinib—CA2—lymph node—cervical cancer	0.000126	0.000994	CbGeAlD
Nilotinib—ABCB1—decidua—cervical cancer	0.000125	0.000987	CbGeAlD
Nilotinib—CYP2D6—female gonad—cervical cancer	0.000125	0.000981	CbGeAlD
Nilotinib—ABCB1—renal system—cervical cancer	0.000123	0.000969	CbGeAlD
Nilotinib—ABCB1—endometrium—cervical cancer	0.000119	0.000937	CbGeAlD
Nilotinib—ABCG2—lymph node—cervical cancer	0.000117	0.00092	CbGeAlD
Nilotinib—ABCB1—mammalian vulva—cervical cancer	0.000115	0.000906	CbGeAlD
Nilotinib—ABCB1—uterus—cervical cancer	0.00011	0.000863	CbGeAlD
Nilotinib—ABCB1—female reproductive system—cervical cancer	9.85e-05	0.000776	CbGeAlD
Nilotinib—ABCB1—female gonad—cervical cancer	8.96e-05	0.000706	CbGeAlD
Nilotinib—ABCB1—vagina—cervical cancer	8.91e-05	0.000702	CbGeAlD
Nilotinib—ABCB1—lymph node—cervical cancer	5.76e-05	0.000454	CbGeAlD
Nilotinib—LCK—Immune System—HLA-DQB1—cervical cancer	1.17e-05	8e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—CTNNB1—cervical cancer	1.16e-05	7.98e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HES1—cervical cancer	1.16e-05	7.96e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—CTNNB1—cervical cancer	1.16e-05	7.94e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—CTNNB1—cervical cancer	1.15e-05	7.89e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HES1—cervical cancer	1.15e-05	7.88e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—STAT3—cervical cancer	1.15e-05	7.88e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—STAT3—cervical cancer	1.14e-05	7.84e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—FGFR3—cervical cancer	1.14e-05	7.8e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—CTNNB1—cervical cancer	1.13e-05	7.75e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—CTNNB1—cervical cancer	1.13e-05	7.75e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—NOTCH1—cervical cancer	1.13e-05	7.74e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—CTNNB1—cervical cancer	1.13e-05	7.72e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MTHFR—cervical cancer	1.12e-05	7.68e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—TERT—cervical cancer	1.12e-05	7.66e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CA9—cervical cancer	1.12e-05	7.65e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—FGFR3—cervical cancer	1.11e-05	7.64e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—CASP8—cervical cancer	1.11e-05	7.63e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—FGFR3—cervical cancer	1.11e-05	7.61e-05	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—EGFR—cervical cancer	1.1e-05	7.57e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—CTNNB1—cervical cancer	1.1e-05	7.56e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—NOTCH1—cervical cancer	1.1e-05	7.54e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD8A—cervical cancer	1.09e-05	7.47e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—STAT3—cervical cancer	1.09e-05	7.47e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NOTCH2—cervical cancer	1.09e-05	7.46e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—STAT3—cervical cancer	1.09e-05	7.45e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—FGFR3—cervical cancer	1.09e-05	7.45e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—FGFR3—cervical cancer	1.08e-05	7.42e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—MTOR—cervical cancer	1.08e-05	7.38e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—CD4—cervical cancer	1.07e-05	7.36e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—NOTCH1—cervical cancer	1.07e-05	7.32e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NOTCH2—cervical cancer	1.07e-05	7.31e-05	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—EGFR—cervical cancer	1.06e-05	7.27e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CASP8—cervical cancer	1.05e-05	7.22e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HES1—cervical cancer	1.05e-05	7.18e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—NOTCH1—cervical cancer	1.05e-05	7.17e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—EGFR—cervical cancer	1.05e-05	7.17e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—EGFR—cervical cancer	1.04e-05	7.16e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—EGFR—cervical cancer	1.04e-05	7.12e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—MTOR—cervical cancer	1.03e-05	7.08e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—CD4—cervical cancer	1.03e-05	7.07e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—FGFR3—cervical cancer	1.03e-05	7.06e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—FGFR3—cervical cancer	1.03e-05	7.03e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—HES1—cervical cancer	1.02e-05	7.01e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TERT—cervical cancer	1.02e-05	6.97e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—MTOR—cervical cancer	1.02e-05	6.96e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CD4—cervical cancer	1.01e-05	6.95e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NOTCH2—cervical cancer	1.01e-05	6.93e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TERT—cervical cancer	1.01e-05	6.91e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—EGFR—cervical cancer	1e-05	6.88e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—STAT3—cervical cancer	1e-05	6.88e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HES1—cervical cancer	9.91e-06	6.79e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—EGFR—cervical cancer	9.9e-06	6.79e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—EGFR—cervical cancer	9.88e-06	6.77e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—STAT3—cervical cancer	9.85e-06	6.75e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—STAT3—cervical cancer	9.85e-06	6.75e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—STAT3—cervical cancer	9.82e-06	6.73e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CA9—cervical cancer	9.72e-06	6.66e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—NOTCH1—cervical cancer	9.62e-06	6.6e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—NOTCH1—cervical cancer	9.62e-06	6.59e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	9.59e-06	6.57e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—CTNNB1—cervical cancer	9.54e-06	6.54e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CASP8—cervical cancer	9.49e-06	6.51e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—EGFR—cervical cancer	9.42e-06	6.46e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—FGFR3—cervical cancer	9.34e-06	6.4e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CASP8—cervical cancer	9.3e-06	6.37e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—MTOR—cervical cancer	9.29e-06	6.37e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—CD4—cervical cancer	9.27e-06	6.36e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CASP8—cervical cancer	9.25e-06	6.34e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—FGFR3—cervical cancer	9.25e-06	6.34e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—EGFR—cervical cancer	9.22e-06	6.32e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—EGFR—cervical cancer	9.18e-06	6.29e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TERT—cervical cancer	9.17e-06	6.29e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—MTOR—cervical cancer	9.16e-06	6.28e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CA9—cervical cancer	9.16e-06	6.28e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—CD4—cervical cancer	9.14e-06	6.27e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—EGFR—cervical cancer	9.12e-06	6.25e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CA9—cervical cancer	9.08e-06	6.22e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—EGFR—cervical cancer	9.05e-06	6.2e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CTNNB1—cervical cancer	9.01e-06	6.17e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MTHFR—cervical cancer	8.99e-06	6.16e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—TERT—cervical cancer	8.97e-06	6.14e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—EGFR—cervical cancer	8.96e-06	6.14e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—EGFR—cervical cancer	8.96e-06	6.14e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HES1—cervical cancer	8.93e-06	6.12e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—EGFR—cervical cancer	8.93e-06	6.12e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—FGFR3—cervical cancer	8.91e-06	6.11e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—EGFR—cervical cancer	8.86e-06	6.07e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CASP8—cervical cancer	8.81e-06	6.04e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NOTCH1—cervical cancer	8.77e-06	6.01e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—EGFR—cervical cancer	8.74e-06	5.99e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HES1—cervical cancer	8.74e-06	5.99e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NOTCH2—cervical cancer	8.74e-06	5.99e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TERT—cervical cancer	8.68e-06	5.95e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NOTCH1—cervical cancer	8.68e-06	5.95e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—MTOR—cervical cancer	8.67e-06	5.94e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD4—cervical cancer	8.65e-06	5.93e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—TP53—cervical cancer	8.6e-06	5.9e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—MTHFR—cervical cancer	8.6e-06	5.89e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—TP53—cervical cancer	8.56e-06	5.87e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—MTOR—cervical cancer	8.46e-06	5.8e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—CD4—cervical cancer	8.44e-06	5.79e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—FGFR3—cervical cancer	8.42e-06	5.77e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HES1—cervical cancer	8.29e-06	5.68e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MTOR—cervical cancer	8.24e-06	5.65e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—CTNNB1—cervical cancer	8.24e-06	5.65e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—FGFR3—cervical cancer	8.23e-06	5.64e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TP53—cervical cancer	8.15e-06	5.59e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—CTNNB1—cervical cancer	8.12e-06	5.57e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	8.05e-06	5.52e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—MTOR—cervical cancer	8.01e-06	5.49e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CD4—cervical cancer	7.99e-06	5.48e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—FGFR3—cervical cancer	7.97e-06	5.46e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NOTCH1—cervical cancer	7.9e-06	5.42e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—STAT3—cervical cancer	7.85e-06	5.38e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MTOR—cervical cancer	7.84e-06	5.37e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TERT—cervical cancer	7.82e-06	5.36e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—MTOR—cervical cancer	7.81e-06	5.35e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD4—cervical cancer	7.8e-06	5.34e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NOTCH1—cervical cancer	7.72e-06	5.29e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CTNNB1—cervical cancer	7.69e-06	5.27e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TERT—cervical cancer	7.66e-06	5.25e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—MTOR—cervical cancer	7.65e-06	5.24e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD4—cervical cancer	7.63e-06	5.23e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CASP8—cervical cancer	7.62e-06	5.22e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—MTOR—cervical cancer	7.61e-06	5.22e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD4—cervical cancer	7.6e-06	5.21e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CASP3—cervical cancer	7.58e-06	5.2e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—EGFR—cervical cancer	7.56e-06	5.18e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—CTNNB1—cervical cancer	7.5e-06	5.14e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NOTCH1—cervical cancer	7.48e-06	5.13e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CTNNB1—cervical cancer	7.31e-06	5.01e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—MTHFR—cervical cancer	7.29e-06	5e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TERT—cervical cancer	7.26e-06	4.98e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—EGFR—cervical cancer	7.26e-06	4.98e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—MTOR—cervical cancer	7.25e-06	4.97e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD4—cervical cancer	7.24e-06	4.96e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MTOR—cervical cancer	7.21e-06	4.94e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CASP3—cervical cancer	7.21e-06	4.94e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CD4—cervical cancer	7.2e-06	4.93e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—STAT3—cervical cancer	7.18e-06	4.92e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FGFR3—cervical cancer	7.18e-06	4.92e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HES1—cervical cancer	7.16e-06	4.91e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—EGFR—cervical cancer	7.14e-06	4.89e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CTNNB1—cervical cancer	7.1e-06	4.86e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—STAT3—cervical cancer	7.08e-06	4.85e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—cervical cancer	7.05e-06	4.83e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FGFR3—cervical cancer	7.03e-06	4.82e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CTNNB1—cervical cancer	6.95e-06	4.76e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CTNNB1—cervical cancer	6.93e-06	4.75e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CTNNB1—cervical cancer	6.78e-06	4.65e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CTNNB1—cervical cancer	6.75e-06	4.63e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NOTCH1—cervical cancer	6.74e-06	4.62e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—STAT3—cervical cancer	6.7e-06	4.59e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FGFR3—cervical cancer	6.66e-06	4.57e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NOTCH1—cervical cancer	6.6e-06	4.52e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MTOR—cervical cancer	6.57e-06	4.5e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—STAT3—cervical cancer	6.54e-06	4.48e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—EGFR—cervical cancer	6.53e-06	4.47e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MTOR—cervical cancer	6.51e-06	4.46e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—EGFR—cervical cancer	6.43e-06	4.41e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CTNNB1—cervical cancer	6.43e-06	4.41e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CTNNB1—cervical cancer	6.39e-06	4.38e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—STAT3—cervical cancer	6.37e-06	4.37e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TERT—cervical cancer	6.28e-06	4.3e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—MTOR—cervical cancer	6.27e-06	4.3e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD4—cervical cancer	6.26e-06	4.29e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NOTCH1—cervical cancer	6.26e-06	4.29e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—STAT3—cervical cancer	6.19e-06	4.24e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—EGFR—cervical cancer	6.09e-06	4.17e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—STAT3—cervical cancer	6.06e-06	4.15e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CASP3—cervical cancer	6.04e-06	4.14e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—STAT3—cervical cancer	6.04e-06	4.14e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CA9—cervical cancer	5.99e-06	4.1e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CASP3—cervical cancer	5.98e-06	4.1e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—EGFR—cervical cancer	5.94e-06	4.07e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MTOR—cervical cancer	5.92e-06	4.06e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—STAT3—cervical cancer	5.91e-06	4.05e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—STAT3—cervical cancer	5.88e-06	4.03e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CTNNB1—cervical cancer	5.82e-06	3.99e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—EGFR—cervical cancer	5.79e-06	3.97e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MTOR—cervical cancer	5.79e-06	3.97e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CD4—cervical cancer	5.78e-06	3.96e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CTNNB1—cervical cancer	5.77e-06	3.95e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FGFR3—cervical cancer	5.76e-06	3.95e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—EGFR—cervical cancer	5.62e-06	3.85e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MTOR—cervical cancer	5.61e-06	3.84e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—STAT3—cervical cancer	5.6e-06	3.84e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—STAT3—cervical cancer	5.57e-06	3.82e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CTNNB1—cervical cancer	5.56e-06	3.81e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—EGFR—cervical cancer	5.5e-06	3.77e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—EGFR—cervical cancer	5.49e-06	3.76e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CASP3—cervical cancer	5.45e-06	3.73e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NOTCH1—cervical cancer	5.41e-06	3.71e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—EGFR—cervical cancer	5.37e-06	3.68e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—EGFR—cervical cancer	5.35e-06	3.66e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—MTHFR—cervical cancer	5.35e-06	3.66e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CTNNB1—cervical cancer	5.25e-06	3.6e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CASP3—cervical cancer	5.16e-06	3.53e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CTNNB1—cervical cancer	5.13e-06	3.52e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EGFR—cervical cancer	5.09e-06	3.49e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—STAT3—cervical cancer	5.08e-06	3.48e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—EGFR—cervical cancer	5.07e-06	3.47e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MTOR—cervical cancer	5.05e-06	3.46e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—STAT3—cervical cancer	5.03e-06	3.45e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CTNNB1—cervical cancer	4.97e-06	3.41e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MTOR—cervical cancer	4.94e-06	3.39e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—cervical cancer	4.86e-06	3.33e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—STAT3—cervical cancer	4.84e-06	3.32e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MTOR—cervical cancer	4.69e-06	3.21e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CASP3—cervical cancer	4.65e-06	3.18e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—cervical cancer	4.62e-06	3.17e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EGFR—cervical cancer	4.61e-06	3.16e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—STAT3—cervical cancer	4.58e-06	3.14e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EGFR—cervical cancer	4.57e-06	3.13e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CASP3—cervical cancer	4.55e-06	3.12e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—MTHFR—cervical cancer	4.53e-06	3.1e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CTNNB1—cervical cancer	4.48e-06	3.07e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—STAT3—cervical cancer	4.47e-06	3.07e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—EGFR—cervical cancer	4.4e-06	3.02e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CTNNB1—cervical cancer	4.38e-06	3e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—STAT3—cervical cancer	4.33e-06	2.97e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CASP3—cervical cancer	4.31e-06	2.96e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—cervical cancer	4.16e-06	2.85e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CTNNB1—cervical cancer	4.16e-06	2.85e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—cervical cancer	4.07e-06	2.79e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MTOR—cervical cancer	4.05e-06	2.78e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MTHFR—cervical cancer	3.94e-06	2.7e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—cervical cancer	3.94e-06	2.7e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—STAT3—cervical cancer	3.9e-06	2.68e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—cervical cancer	3.87e-06	2.65e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—cervical cancer	3.84e-06	2.63e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—STAT3—cervical cancer	3.82e-06	2.62e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CASP3—cervical cancer	3.73e-06	2.56e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MTHFR—cervical cancer	3.72e-06	2.55e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MTHFR—cervical cancer	3.68e-06	2.52e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—STAT3—cervical cancer	3.62e-06	2.48e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CTNNB1—cervical cancer	3.59e-06	2.46e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—cervical cancer	3.55e-06	2.43e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—cervical cancer	3.49e-06	2.39e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—cervical cancer	3.47e-06	2.38e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—cervical cancer	3.31e-06	2.27e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—cervical cancer	3.29e-06	2.26e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—STAT3—cervical cancer	3.13e-06	2.15e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—cervical cancer	2.98e-06	2.04e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—cervical cancer	2.92e-06	2e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—cervical cancer	2.85e-06	1.95e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—cervical cancer	2.76e-06	1.89e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MTHFR—cervical cancer	2.43e-06	1.67e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—cervical cancer	2.39e-06	1.64e-05	CbGpPWpGaD
